|
[1]
|
Cruz-Jentoft, A.J., Bahat, G., Bauer, J., et al. (2019) Sarcopenia: Revised European Consensus on Definition and Diag-nosis. Age Ageing, 48, 16-31. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
中华医学会骨质疏松和骨矿盐疾病分会. 肌少症共识[J]. 中华骨质疏松和骨矿盐疾病杂志, 2016, 9(3): 215-227.
|
|
[3]
|
Ponziani, F.R. and Gasbarrini, A. (2018) Sarcopenia in Patients with Advanced Liver Disease. Current Protein & Peptide Science, 19, 681-691. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Mauro, E., Crespo, G., Martinez-Garmendia, A., et al. (2020) Cystatin C and Sarcopenia Predict Acute on Chronic Liver Failure Development and Mortality in Patients on the Liver Transplant Waiting List. Transplantation, 104, el88- e198. [Google Scholar] [CrossRef]
|
|
[5]
|
Kamo, N., Kaido, T., Hamaguchi, Y., et al. (2019) Impact of Sarcopenic Obesity on Outcomes in Patients Undergoing Living Donor Liver Transplantation. Clinical Nutrition, 38, 2202-2209. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
van Vugt, J.L.A., Buettner, S., Alferink, L.J.M., et al. (2018) Low Skeletal Muscle Mass Is Associated with Increased Hospital Costs in Patients with Cirrhosis Listed for Liv-er Transplantation—A Retrospective Study. Transplant International, 31, 165-174. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Lai, J.C., Tandon, P., Bernal, W., et al. (2021) Malnutrition, Frailty, and Sarcopenia in Patients with Cirrhosis: 2021 Practice Guidance by the American Association for the Study of Liver Dis-eases. Hepatology, 74, 1611-1644. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Traub, J., Reiss, L., Aliwa, B. and Stadlbauer, V. (2021) Malnutrition in Patients with Liver Cirrhosis. Nutrients, 13, Article 540. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Palmer, L.B., Kuftinec, G., Pearlman, M. and Green, C.H. (2019) Nutrition in Cirrhosis. Current Gastroenterology Reports, 21, Arti-cle No. 38 [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Nishikawa, H., Enomoto, H., Nishiguchi, S. and Iijima, H. (2020) Liver Cirrhosis and Sarcopenia from the Viewpoint of Dysbiosis. International Journal of Molecular Sciences, 21, Article 5254. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Lee, J.H. and Jun, H.S. (2019) Role of Myokines in Regulating Skeletal Muscle Mass and Function. Frontiers in Physiology, 10, Article 42. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Nishikawa, H., Enomoto, H., Ishii, A., et al. (2017) Elevatedse-rummyostatin Level Is Associated with Worse Survival in Patients with Liver Cirrhosis. Journal of Cachexia, Sarcopenia and Muscle, 8, 915-925. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Dasarathy, S. and Merli, M. (2016) Sarcopenia from Mechanism to Diag-nosis and Treatment in Liver Disease. Journal of Hepatology, 65, 1232-1244. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Sinclair, M., Gow, P.J., Grossmann, M. and Angus, P.W. (2016) Review Article: Sarcopenia in Cirrhosis—Aetiology, Implications and Potential Therapeutic Interventions. Alimentary Pharmacology & Therapeutics, 43, 765-777. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Kim, J.H., Kang, S.H., Lee, M., et al. (2020) Serum Myostatin Predicts the Risk of Hepatocellular Carcinoma in Patients with Alcoholic Cirrhosis: A Multicenter Study. Cancers, 12, Article 3347. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Yoshio, S., Shimagaki, T., Hashida, R., et al. (2021) Myostatin as a Fibroblast Activating Factor Impacts on Postoperative Outcome in Patients with Hepatocellular Carcinoma. Hepatology Research, 51, 803-812. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Thapaliya, S., Runkana, A., Mcmullen, M.R., et al. (2014) Alco-hol-Induced Autophagy Contributes to Loss in Skeletal Muscle Mass. Autophagy, 10, 677-690. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Montgomery, J. and Englesbe, M. (2019) Sarcopenia in Liver Transplanta-tion. Current Transplantation Reports, 6, 7-15. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Kumar, A., Davuluri, G., Silva, R.N.E., et al. (2017) Ammonia Lowering Reverses Satcopenia of Cirrhosis by Restoring Skeletal Muscle Proteostasis. Hepatology, 65, 2045-2058. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Abrigo, J., Elorza, A.A., Riedel, C.A., et al. (2018) Role of Oxidative Stress as Key Regulator of Muscle Wasting during Cachexia. Oxidative Medicine and Cellular Longevity, 2018, Article ID: 2063179. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Merli, M. (2020) Nutrition in Cirrhosis: Dos and Don’ts. Journal of Hepatology, 73, 1563-1565. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Takahashi, Y. (2017) The Role of Growth Hormcze and Insu-lin-Like Growth Factor-I in the Liver. International Journal of Molecular Sciences, 18, Article 1447. [Google Scholar] [CrossRef]
|
|
[23]
|
Adamek, A. and Kasprzak, A. (2018) Insulin-Like Growth Factor (IGF) System in Liver Diseases. International Journal of Molecular Sciences, 19, Article 1308. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Chen, L.K., Woo, J., Assantachai, P., et al. (2020) Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. Journal of the American Medi-cal Directors Association, 21, 300-307.E2. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
Vellas, B., Fielding, R.A., Bens, C., et al. (2018) Implications of ICD-10 for Sarcopenia Clinical Practice and Clinical Trials: Report by the International Conference on Frailty and Sarco-penia Research Task Force. The Journal of Frailty & Aging, 7, 2-9. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Stegenga, H., Haines, A., Jones, K., et al. (2014) ldentification, Assess-ment, and Management of Overweight and Obesity: Summary of Updated NICE Guidance. The BMJ, 349, g6608. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Dichi, J.B., Dichi, L., Maior, R., et al. (2001) Whole-Body Protein Turno-ver in Malnourished Patients with Child Class B and C Cirrhosison Diets Low to High in Protein Energy. Nutrition, 17, 239-242. [Google Scholar] [CrossRef]
|
|
[28]
|
Hardee, J.P. and Lynch, G.S. (2019) Current Pharmacother-apies for Sarcopenia. Expert Opinion on Pharmacotherapy, 20, 1645-1657. [Google Scholar] [CrossRef] [PubMed]
|
|
[29]
|
Hanai, T., Shiraki, M., Nishimura, K., et al. (2015) Sarcope-nia Impairs Prognosis of Patients with Liver Cirrhosis. Nutrition, 31, 193-199. [Google Scholar] [CrossRef] [PubMed]
|
|
[30]
|
European Association for the Study of the Liver (2019) EASL Clin-ical Practice Guidelines on Nutrition in Chronic Liver Disease. Journal of Hepatology, 70, 172-193. [Google Scholar] [CrossRef] [PubMed]
|
|
[31]
|
Schiaffino, S., Dyar, K.A., Ciciliot, S., Blaauw, B. and Sandri, M. (2013) Mechanisms Regulating Skeletal Muscle Growth and Atrophy. FEBS Journal, 280, 4294-4314. [Google Scholar] [CrossRef] [PubMed]
|
|
[32]
|
Plauth, M., Bernal, W., Dasarathy, S., et al. (2019) ESPEN Guideline on Clinical Nutrition in Liver Disease. Clinical Nutrition, 38, 485-521. [Google Scholar] [CrossRef] [PubMed]
|
|
[33]
|
Hernández-Conde, M., Llop, E., Gómez-Pimpollo, L., et al. (2021) Adding Branched-Chain Amino Acids to an Enhanced Standard-of-Care Treatment Improves Muscle Mass of Cirrhotic Patients with Sarcopenia: A Placebo-Con- trolled Trial. The American Journal of Gastroenterology, 116, 2241-2249. [Google Scholar] [CrossRef] [PubMed]
|
|
[34]
|
Kitajima, Y., Takahashi, H., Akiyama, T., et al. (2018) Sup-plementation with Branched-Chain Amino Acids Ameliorates Hypoalbuminemia, Prevents Sarcopenia, and Reduces Fat Accumulation in the Skeletal Muscles of Patients with Liver Cirrhosis. Journal of Gastroenterology, 53, 427-437. [Google Scholar] [CrossRef] [PubMed]
|
|
[35]
|
Malaguarnera, M., Vacante, M., Giordano, M., et al. (2011) Oralacetyl-L-Carnitine Therapy Reduces Fatigue in oVert Hepatic Encephalopathy: A Randomized, Double-Blind, Pla-cebo-Controlled Study. The American Journal of Clinical Nutrition, 93, 799-808. [Google Scholar] [CrossRef] [PubMed]
|
|
[36]
|
Bischoff, S.C., Bernal, W., Dasarathy, S., et al. (2020) ESPEN Prac-tical Guideline: Clinical Nutrition in Liver Disease. Clinical Nutrition, 39, 3533-3562. [Google Scholar] [CrossRef] [PubMed]
|
|
[37]
|
中华医学会肝病学分会, 中华医学会消化病学分会. 终末期肝病临床营养指南[J]. 中华肝脏病杂志, 2019, 27(5): 330-342.
|
|
[38]
|
Tandon, P., Ismond, K.P., Riess, K., et al. (2018) Exercise in Cirrhosis: Translating Evidence and Experience to Practice. Journal of Hepatology, 69, 1164-1177. [Google Scholar] [CrossRef] [PubMed]
|
|
[39]
|
Duarte-Rojo, A., Ruiz-Margain, A., Montano-Lozaa, J., et al. (2018) Exercise and Physical Activity for Patients with End-Stage Liver Disease: Improving Functional Status and Sar-copenia While on the Transplant Waiting List. Liver Transplant, 24, 122-139. [Google Scholar] [CrossRef] [PubMed]
|
|
[40]
|
肖慧娟, 韩涛. 肝硬化患者营养不良、肌肉减少症及骨质疏松的防治[J]. 临床肝胆病杂志, 2021, 37(1): 26-30.
|
|
[41]
|
Becker, C., Lord, S.R., Studenski, S.A., et al. (2015) Myostatin Antibody (LY2495655) in Older Weak Fallers: A Proof-of-Concept, Randomised, Phase 2 Trial. The Lancet Diabetes and Endocrinology, 3, 948-957. [Google Scholar] [CrossRef]
|
|
[42]
|
Rooks, D. and Roubenoff, R. (2019) Development of Phar-macotherapies for the Treatment of Sarcopenia. The Journal of Frailty & Aging, 8, 120-130. [Google Scholar] [CrossRef] [PubMed]
|
|
[43]
|
Yurci, A., Yucesoy, M., Unluhizarci, K., et al. (2011) Effects of Testos-terone Gel Treatment in Hypogonadal Men with Liver Cirrhosis. Clinics and Research in Hepatology and Gastroenter-ology, 35, 845-854. [Google Scholar] [CrossRef] [PubMed]
|
|
[44]
|
Tandon, P., Montano-Loza, A.J., Lai, J.C., Dasarathy, S. and Merli, M. (2021) Sarcopenia and Frailty in Decompensated Cirrhosis. Journal of Hepatology, 75, S147-S162. [Google Scholar] [CrossRef] [PubMed]
|
|
[45]
|
Aguirre, F., Abrigo, J., Gonzalez, F., et al. (2020) Protective Effect of Angiotensin 1-7 on Sarcopenia Induced by Chronic Liver Disease in Mice. International Journal of Molecular Sci-ences, 21, Article 3891. [Google Scholar] [CrossRef] [PubMed]
|
|
[46]
|
刘晓蕾, 岳冀蓉, 乔闰娟, 等. 肠道菌群在肌少症发病机制中的作用[J]. 实用老年医学, 2019, 33(9): 840-843.
|